Takeda Pharmaceutical Co. Ltd. ADR (TAK): Price and Financial Metrics

Takeda Pharmaceutical Co. Ltd. ADR (TAK): $13.10

0.09 (+0.69%)

POWR Rating

Component Grades

Momentum

D

Stability

B

Sentiment

Quality

C

TAK Price/Volume Stats

Current price $13.10 52-week high $15.08
Prev. close $13.01 52-week low $12.57
Day low $13.02 Volume 1,848,700
Day high $13.19 Avg. volume 1,830,433
50-day MA $13.71 Dividend yield 4.11%
200-day MA $13.79 Market Cap 41.68B

TAK Stock Price Chart Interactive Chart >


Takeda Pharmaceutical Co. Ltd. ADR (TAK) Company Bio


The Takeda Pharmaceutical Company Limited (武田薬品工業株式会社, Takeda Yakuhin Kōgyō kabushiki gaisha[takeꜜda jakɯçiŋ koꜜːɡʲoː] is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following its merger with Shire). The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neurosciencegastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-kuOsaka, and it has an office in NihonbashiChuoTokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. (Source:Wikipedia)


TAK Latest News Stream


Event/Time News Detail
Loading, please wait...

TAK Latest Social Stream


Loading social stream, please wait...

View Full TAK Social Stream

TAK Price Returns

1-mo -2.09%
3-mo -10.38%
6-mo 2.81%
1-year -5.02%
3-year 0.60%
5-year -27.85%
YTD -6.48%
2023 -7.00%
2022 16.87%
2021 -23.58%
2020 -5.97%
2019 19.31%

TAK Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full TAK Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!